Digitalni repozitorij raziskovalnih organizacij Slovenije

Izpis gradiva
A+ | A- | Pomoč | SLO | ENG

Naslov:Adjuvant treatment of breast cancer patients with trastuzumab
Avtorji:ID Matos, Erika (Avtor)
ID Čufer, Tanja (Avtor)
Datoteke:.pdf PDF - Predstavitvena datoteka, prenos (3,80 MB)
MD5: 94EB2103C823D7E3BE4ACD9135729F26
 
Jezik:Angleški jezik
Tipologija:1.02 - Pregledni znanstveni članek
Organizacija:Logo OI - Onkološki inštitut Ljubljana
Povzetek:Background. Trastuzumab is a monoclone antibody directed against HER2 receptors that are overexpressed in approximately 20% of breast cancer patients. The present paper presents five clinical trials in which trastuzumabwas applied in breast cancer patients in adjuvant setting. The results of all the trials consistently demonstrate a high efficacy of this target drug in the patients with HER2 positive tumours. So far, no formal guidelines for using trastuzumab in adjuvant setting for breast cancer have been approved. The reasons are many: (i) mean observation time in the studies done so far was considerably short; (ii) the drug was used according to different schedules, (iii) the overall time of treatment with trastuzumab was different in each trial, (iv) late side effects of treatment with trastuzumab are inadequately investigated, and (v) nobody can so far say for sure for which HER2 status patients therapy with trastuzumab is really beneficial. Conclusions. Trastuzumab is definitely very helpful in the treatment of the HER2-positive breast cancer patients that are hormone-independent and of anatomically larger tumours; but, what the absolute benefit of trastuzumab therapy in the treatment of small hormone-dependent tumours is remains a mystery. Incidentally, it must be borne in mind that cardiotoxicity, the well known side effect, may put particularly elderly patients at risk of death, thus beating any treatment advantages down. It has also not been yet resolved at what time it would be most appropriate to start with the therapy with trastuzumab, what would be the optimal duration of the therapy and whether trastuzumab is to be administered concurrently with chemotherapy or immediately after it? What is the optimal treatment duration, one or two yearsor only a few months? In addition there is still a question of optimal HER2 status determination and which HER2 status predicts for trastuzumab benefit. (Abstract truncated at 2000 characters)
Status publikacije:Objavljeno
Verzija publikacije:Objavljena publikacija
Datum objave:01.09.2007
Založnik:Association of Radiology and Oncology
Leto izida:2007
Št. strani:str. 115-122
Številčenje:Vol. 41, no. 3
Izvor:Ljubljana
PID:20.500.12556/DiRROS-18240 Novo okno
UDK:616-006
ISSN pri članku:1318-2099
COBISS.SI-ID:23500761 Novo okno
Avtorske pravice:by Authors
Opomba:BSDOCID134804;
Datum objave v DiRROS:22.02.2024
Število ogledov:756
Število prenosov:169
Metapodatki:XML DC-XML DC-RDF
:
MATOS, Erika in ČUFER, Tanja, 2007, Adjuvant treatment of breast cancer patients with trastuzumab. Radiology and oncology [na spletu]. 2007. Vol. 41, no. 3, p. 115–122. [Dostopano 29 marec 2025]. Pridobljeno s: https://dirros.openscience.si/IzpisGradiva.php?lang=slv&id=18240
Kopiraj citat
  
Objavi na:Bookmark and Share


Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše podrobnosti ali sproži prenos.

Gradivo je del revije

Naslov:Radiology and oncology
Skrajšan naslov:Radiol. oncol.
Založnik:Slovenian Medical Society - Section of Radiology, Croatian Medical Association - Croatian Society of Radiology
ISSN:1318-2099
COBISS.SI-ID:32649472 Novo okno

Sekundarni jezik

Jezik:Slovenski jezik
Naslov:Dopolnilno zdravljenje bolnic z rakom dojke s transtuzumabom


Nazaj